Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 25th, 2026 – Happy Memorial Day!

LECO_Weekly-Healthcare-News_5-25-2026Download
  1. Oura Inc. (ŌURA) submits confidential draft Form S-1 to the SEC for a proposed initial public offering of its common stock. San Francisco-based Oura Inc., the smart-ring maker behind the Oura Ring, has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range have not yet been determined, with the IPO expected after the SEC completes its review. Oura was valued at $11 billion in October 2025 following a $900 million Series E and is projected to generate roughly $2 billion in 2026 revenue. The company supports over 1,200 wellness and medical partners. (Link)
  2. Medtronic (NYSE: MDT) to Acquire SPR Therapeutics for $650 Million Medtronic plc has agreed to acquire SPR Therapeutics, a pioneer in minimally invasive peripheral nerve stimulation (PNS) technology, in an all-cash transaction valued at $650 million. The deal brings in SPR’s FDA-cleared SPRINT PNS System, a temporary, non-opioid solution for chronic pain that has demonstrated strong clinical outcomes with lower risk compared to permanent implants. For Medtronic, this bolsters its neuromodulation portfolio and accelerates its shift toward less invasive, drug-free pain management therapies amid growing demand for opioid alternatives. The acquisition is expected to close in the first half of Medtronic’s fiscal 2027 and should be immediately accretive to earnings. (Link)
  3. Eli Lilly and Company (NYSE: LLY) Acquires Engage Bio to Accelerate Development of Non-Viral Genetic Medicines Eli Lilly and Company has acquired Engage Bio, a preclinical biotechnology company focused on non-viral delivery platforms for genetic medicines. The deal provides Lilly with proprietary technology aimed at improving the safety and efficacy of gene editing and RNA-based therapies. Engage Bio’s platform is designed to overcome key limitations of current viral vector approaches, potentially enabling broader application of genetic medicines. This acquisition reinforces Lilly’s commitment to building leadership in next-generation genetic medicine platforms. (Link)
  4. BrainsWay Ltd. (NASD: BWAY; TASE: BWAY) invests $1.5M for a minority stake in Hopemark Health, operated by Advanced Psychiatric Management LLC under parent APS Innovations LLC. Burlington, Mass.-based BrainsWay Ltd. (NASDAQ: BWAY; TASE: BWAY) has entered a strategic equity financing agreement with APS Innovations LLC, the parent of Advanced Psychiatric Management LLC, which operates Chicago-area mental health clinics under the Hopemark Health brand. BrainsWay is investing $1.5 million for a minority position via a preferred, annually compounding security, with the potential for an additional $1.5 million through milestone-based investments and a redemption mechanism. CEO Hadar Levy described the deal as part of BrainsWay’s strategy to partner with growth-oriented clinical platforms and expand access to interventional psychiatry solutions including Deep TMS. BrainsWay is valued at roughly $606 million. (Link)
  5. QT Imaging Holdings, Inc. (NASD: QTI) closes a $10M underwritten public offering with both existing and new investors participating. Novato, Calif.-based QT Imaging Holdings, Inc. (NASDAQ: QTI) has completed an underwritten public offering of 2,000,000 shares of common stock or pre-funded warrants, generating gross proceeds of approximately $10 million. The offering was priced at $5.00 per share, with pre-funded warrants at $4.9999, and saw participation from both existing and new investors. Net proceeds will be used for working capital and general corporate purposes. QTI shares had declined 24% over the week prior to closing, trading at $5.49 with a market capitalization of $65.63 million. QT Imaging develops radiation-free, ultrasound-based breast imaging technology and recently posted strong Q1 2026 revenue growth. (Link)
  6. Innovaccer Inc. acquires CaduceusHealth (reported at $66M) to build out its agentic revenue cycle management platform. San Francisco-based healthcare AI company Innovaccer Inc. has acquired CaduceusHealth, a nationally recognized revenue cycle management services provider, in a reported $66 million asset deal — Innovaccer’s fifth strategic acquisition. Founded in 1997, CaduceusHealth manages billing, claims, and denial resolution for nearly 4,000 providers and handles $5 billion in gross patient charges annually across every major EHR. The transaction expands Innovaccer’s Flow suite into full-stack RCM capabilities, unifying scheduling, patient engagement, and end-to-end revenue cycle workflows for ambulatory care providers. The integrated platform leverages Innovaccer’s Gravity AI infrastructure to address the nearly $20 billion lost annually to avoidable denials. (Link)
  7. Nexalin Technology, Inc. (NASD: NXL) acquires PONM, Inc. from GreenLight Ventures, LLC for $1.3M in stock. Houston-based Nexalin Technology, Inc. (NASDAQ: NXL) has closed the acquisition of PONM, Inc. from GreenLight Ventures, LLC for $1.3 million payable in Nexalin common stock issued across four tranches, with 959,016 shares delivered at closing. PONM is the AI-integrated digital health platform powering Nexalin’s HALO Clarity neurostimulation program and Nexalin NeuroCare virtual clinic, already deployed at UC San Diego. Nexalin gains ownership of PONM and an exclusive license to proprietary software for remote patient monitoring, EHR functionality, and virtual-clinic management. GreenLight becomes a significant Nexalin equity holder and continues engineering, cybersecurity, and regulatory support under a 24-month collaboration agreement. (Link)
  8. GHO Capital and CBC Group Merge to Create $21 Billion Global Healthcare Investment Platform GHO Capital and CBC Group have completed a transformational merger to form one of the world’s largest dedicated healthcare private equity firms with over $21 billion in assets under management. The combined platform brings together GHO’s European mid-market expertise with CBC’s strong Asia-Pacific presence and deep sector relationships. The merger significantly enhances the firm’s ability to pursue larger transactions and cross-border opportunities across healthcare services, biotech, and medtech. For limited partners, this creates a truly global healthcare investor with greater scale, sourcing advantages, and operational resources. (Link)
  9. Grundium (backed by EW Healthcare Partners) Acquires Visiopharm to Create Integrated Precision Pathology Platform Grundium Oy, backed by EW Healthcare Partners, has acquired Visiopharm A/S, a leader in AI-powered image analysis software for digital pathology. The strategic combination merges Grundium’s high-quality digital slide scanners with Visiopharm’s advanced AI algorithms for automated tissue analysis and biomarker quantification. The deal creates a comprehensive end-to-end precision pathology solution that improves diagnostic accuracy, reduces turnaround times, and supports pathologists facing increasing workloads. For investors, this positions the combined platform to capture significant share in the rapidly growing computational pathology market driven by oncology and personalized medicine. (Link)
  10. Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for Biopharma and Healthcare Cohere has acquired Reliant AI, a biopharma-specialized AI company with operations in Montreal and Berlin. The transaction strengthens Cohere’s vertical AI capabilities in regulated industries by integrating Reliant’s domain-specific models optimized for clinical, regulatory, and research workflows. This move enhances Cohere’s ability to deliver sovereign, privacy-compliant AI solutions for large pharmaceutical and healthcare enterprises. The acquisition underscores the accelerating trend of big tech players deepening vertical specialization to address the unique data governance and compliance requirements of life sciences. (Link) (Link)
  11. Pillr Health (backed by Water Street Healthcare Partners) acquires CaptureRx for undisclosed terms to expand its 340B pharmacy solutions platform. Boca Raton, Fla.-based Pillr Health — a 340B-focused pharmacy optimization platform recently acquired by Water Street Healthcare Partners from Renovus Capital Partners — has acquired San Antonio-based CaptureRx, a 340B technology and services organization. Terms were not disclosed. The transaction extends Pillr Health’s reach to more than 500 hospitals, health systems, and federally qualified health centers nationwide and consolidates CaptureRx’s 20-plus years of 340B expertise into Pillr’s integrated platform spanning split billing, contract pharmacy administration, entity-owned pharmacy management, referral capture, and compliance support. CEO Skip Devanny will lead the combined organization as covered entities face mounting 340B regulatory and compliance pressure. (Link)
  12. $200M Merger of Dominion Aesthetic Technologies Inc. and BellaMia Technologies Inc. Creates New Laser Device Leader Dominion Aesthetic Technologies and BellaMia Technologies have merged in a transaction valued at approximately $200 million to create a leading player in medical aesthetics laser devices. The combined company brings together complementary portfolios of energy-based devices for body contouring, skin rejuvenation, and hair removal. The merger is expected to deliver meaningful revenue and cost synergies while accelerating innovation and international expansion. Backed by strong private equity sponsorship, the new entity is well-positioned to capitalize on the continued growth of the global aesthetic medicine market. (Link)
  13. Endologix Acquires Pounce Thrombectomy System to Expand Vascular Intervention Portfolio Endologix has acquired the Pounce Thrombectomy System, a novel mechanical thrombectomy technology for arterial clot removal. The deal expands Endologix’s peripheral vascular portfolio beyond its core AAA stent graft business into the high-growth thrombectomy segment. Pounce offers a differentiated, low-profile solution for rapid clot extraction in acute limb ischemia cases. The acquisition supports Endologix’s strategy to build a more diversified vascular intervention platform and improve patient outcomes in peripheral arterial disease. (Link)
  14. Everis Medical Announces Acquisition of Hood Laboratories to Expand Head, Neck, and Airway Management Portfolio Everis Medical has acquired Hood Laboratories, a specialist in airway management and head/neck surgical products. The transaction broadens Everis’ product offering in otolaryngology and anesthesia with Hood’s established portfolio of silicone stents, tracheostomy tubes, and related airway devices. This strategic add-on enhances Everis’ position in niche ENT and airway markets while providing cross-selling opportunities across its existing customer base. The acquisition reflects continued consolidation in the fragmented medical device specialty markets. (Link)
  15. Lexitas Pharma Services Acquires Erie Retina Research and Element Erie Lexitas Pharma Services, a leading ophthalmology-focused contract research organization (CRO), has acquired Erie Retina Research (CASExERIE) and Element Erie. The transaction significantly expands Lexitas’ clinical trial capabilities in retinal diseases and strengthens its presence in the Midwest. The acquired sites bring established investigator networks, experienced staff, and a robust pipeline of ongoing retinal studies. This acquisition bolsters Lexitas’ position as a premier ophthalmology CRO amid rising demand for specialized expertise in macular degeneration, diabetic retinopathy, and other vision-threatening conditions. (Link)
  16. Midlothian Dermatology Joins Epiphany Dermatology Epiphany Dermatology, a leading physician-led dermatology practice platform, has acquired Midlothian Dermatology in Texas. The transaction expands Epiphany’s footprint in the Dallas-Fort Worth metro area and adds a well-established clinical team with strong patient loyalty. This continues Epiphany’s disciplined roll-up strategy in high-growth dermatology markets, supported by robust demand for medical, surgical, and cosmetic services. The deal reflects ongoing consolidation in the dermatology sector as independent practices seek scale, operational support, and capital for expansion. (Link)
  17. Ballantyne Plastic Surgery acquired by Alexis Miller and Gen3 Innovations Lab Aesthetics and Wellness Group, with capital partnership from New Majority Capital. Charlotte, N.C.-based Ballantyne Plastic Surgery, a 30-plus-year aesthetic practice founded by Thomas G. Liszka, M.D., has been acquired by Alexis Miller and Gen3 Innovations Lab Aesthetics and Wellness Group, with capital partnership from impact-focused investor New Majority Capital. Gen3 is an entrepreneurship-through-acquisition (ETA) search-fund vehicle targeting cash-flowing businesses with enterprise value between $5 million and $20 million. Miller, who holds an MBA from Chicago Booth and previously held roles at TikTok, Facebook, and Adobe, will serve as principal and managing partner. The acquisition continues the practice’s offerings of surgical and non-surgical aesthetic procedures in the Charlotte community. (Link)
  18. Clutch Health acquires Perx Health’s U.S. operations for undisclosed terms, marking its second healthcare acquisition. Philadelphia-based Clutch, an AI-powered retention, loyalty and engagement platform serving commerce and healthcare, has acquired the U.S. operations of digital health engagement company Perx Health. Terms were not disclosed. This is Clutch’s second healthcare acquisition, following its 2025 acquisition of Reciprocity Health. Perx’s behavioral-science-driven mobile platform — used by major U.S. health plans and provider organizations — drives medication adherence, treatment plan completion, and chronic condition self-management through gamification and personalized incentives. Perx CEO Scott Taylor will operate within Clutch Health reporting to CEO Craig Hauben, combining Perx’s engagement engine with Reciprocity’s incentive science and Clutch’s AI and data platform. (Link)
  19. Predict Health acquires the Insightin Health platform (inGAGE™) for undisclosed terms to build a unified AI solution for payer intelligence and member engagement. Arlington, Va.-based Predict Health has acquired the Insightin Health platform, an AI-powered healthcare engagement and orchestration solution serving Medicare Advantage, Medicaid, DSNP, ACA, and Commercial health plans. Financial terms were not disclosed. The combined platform will support health plans serving more than 3 million covered lives across 25 states and powers millions of member interactions annually. Predict Health leverages over 800 million healthcare and consumer data records and 300 million-plus member profiles, while the acquired inGAGE™ platform adds real-time journey orchestration, next-best-action decisioning, and omnichannel outreach across phone, text, IVR, email, direct mail, and digital channels. (Link)
  20. InSphero AG Acquires PhenoVista Biosciences Inc. to Expand Advanced 3D Cell-based Assay Capabilities InSphero AG has acquired PhenoVista Biosciences, a provider of advanced 3D cell-based assay services and imaging solutions. The transaction significantly strengthens InSphero’s position in the rapidly growing 3D microtissue and organoid market for drug discovery and toxicology. PhenoVista brings proprietary assay development expertise and high-content imaging capabilities that complement InSphero’s spheroid and organoid platform technologies. The acquisition enhances InSphero’s ability to support pharmaceutical clients with more predictive, human-relevant preclinical models.(Link)

Venture Deals and Other

  1. Century Health raises $5M Seed led by Origin Ventures with participation from InnovateHealth Ventures, 25madison, Next Play Ventures, 2048 Ventures, Alumni Ventures, and angel investor Zorba Lieberman. Century Health, a New York-based healthcare AI company, has closed an oversubscribed $5 million Seed round. The financing was led by Origin Ventures, the Chicago-based early-stage venture firm focused on the “digital native economy,” with participation from InnovateHealth Ventures, 25madison, Next Play Ventures, 2048 Ventures, Alumni Ventures, and strategic angel investors including Zorba Lieberman alongside clinician angels. The capital will fund expansion of partnerships with pharmaceutical and life sciences companies, growth of Century’s specialty provider data network, and enhancements to its AI-powered CHARM platform that converts unstructured EHR data into research-ready real-world evidence across neurology, nephrology, ophthalmology, and other specialties. (Link)
  2. Commure raises $70M at a $7B post-money valuation led by General Catalyst with participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis. Mountain View-based Commure, the AI platform for healthcare operations, has banked $70 million in fresh financing at a $7 billion post-money valuation, taking total funding to $750 million. General Catalyst led the round with participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis. The company, which merged with Athelas in 2023, deploys agentic AI and ambient workflow tools across more than 500 healthcare organizations and 3,000-plus care sites, including over 130 of the country’s largest health systems such as Tenet Healthcare and HCA Healthcare. Proceeds will scale its revenue cycle and practice management platform, enhance agentic AI infrastructure, and expand globally. (Link)
  3. CVRD Health raises $5M Seed led by Upfront Ventures with participation from Waterline Ventures and Distributed Ventures. CVRD Health has closed a $5 million Seed round led by Upfront Ventures, with participation from Waterline Ventures and Distributed Ventures. Upfront’s general partner Kevin Zhang highlighted CVRD’s positioning in the underserved government contracting market, where federal contracting exceeds $773 billion annually. The proceeds will fund platform development, expansion of the company’s compliance and member advocacy teams, and broader adoption among federal government contractors nationwide. CVRD modernizes benefits compliance for contractors under the Service Contract Act, Davis-Bacon Related Acts, and prevailing wage laws, pairing real-time benefit tracking with an Individual Coverage Health Reimbursement Arrangement (ICHRA) and dedicated member advocates. (Link)
  4. Kin Health raises $9M Seed led by Maveron with participation from Town Hall Ventures, Flex Capital, Eniac Ventures, The Family Fund, Pear VC, Watershed Ventures, Foundry Square Capital, and angel investors including GoodRx co-founders Doug Hirsch and Trevor Bezdek, Nabeel Quryshi, Jay Desai, Alex Cohen, and Saharsh Patel. Los Angeles-based Kin Health, a free patient-facing app that records and summarizes medical visits, has raised a $9 million Seed round led by Maveron. Participation came from Town Hall Ventures, Flex Capital, Eniac Ventures, The Family Fund, Pear VC, Watershed Ventures, Foundry Square Capital, and a deep angel roster including GoodRx co-founders Doug Hirsch and Trevor Bezdek (who join as founding partners and executive chairmen), Nabeel Quryshi, Jay Desai, Alex Cohen, Saharsh Patel, and more than 30 physicians. Funding will expand the consumer product, deepen Kin’s longitudinal health-record capability, build a clinical quality engine, and develop downstream care navigation features. (Link)
  5. Nourish raises $100M Series C led by Menlo Ventures with participation from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners. New York-based Nourish, the largest dietitian-led metabolic health clinic in the U.S., has closed a $100 million Series C at a reported $1.75 billion post-money valuation, taking total funding to $215 million. Menlo Ventures led the round, with partner J.P. Sanday joining the board, alongside Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners. Capital will grow Nourish’s network of 10,000-plus registered dietitians, accelerate AI-agent investment for patients and providers, expand its metabolic clinic care model with GLP-1 integration, and deepen partnerships with health plans, employers, and health systems. (Link)
  6. Vi (Vi Labs) completes a $145M transaction at a $1.64B valuation with shareholders including General Atlantic, Revelstoke, 1902 Capital (managed by The Pritzker Organization), Square Peg, Savano Capital, and Island Green. New York-based Vi, the enterprise-AI platform for healthcare, life sciences, and wellness, has completed a $145 million transaction valuing the company at $1.64 billion alongside the launch of a new suite of vertically specialized AI agents. The transaction consisted of both secondary and primary capital, supporting top talent retention and acquisition, platform and new product investment, and balance sheet strengthening. The company’s shareholders include General Atlantic, Revelstoke, 1902 Capital managed by The Pritzker Organization, Square Peg, Savano Capital, Island Green and others. Vi serves 100-plus enterprise customers, supports more than 190 million lives, and has helped bring 50-plus drugs to market. (Link)
  7. cAMPfield Therapeutics Raises $180M Series A to Advance I&I Pipeline cAMPfield Therapeutics, a San Diego-based inflammation and immunology (I&I) company led by former Roivant executive Bill Gerhart, has closed a $180 million Series A financing. The round was led by Mountainfield Venture Partners with strong participation from a marquee syndicate including Novo Holdings, RA Capital, Frazier Life Sciences, Deep Track Capital, Forbion, Abingworth, Venrock, and Longitude Capital. Proceeds will be used to advance cAMPfield’s pipeline of licensed assets targeting autoimmune and inflammatory diseases, as well as support clinical development and business development activities. The substantial raise reflects continued strong investor appetite for high-quality I&I platforms in a competitive therapeutics landscape. (Link)
  8. Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology Blank Bio has closed a Seed financing round and entered a strategic collaboration with PacBio. The partnership combines Blank Bio’s AI expertise with PacBio’s long-read sequencing technology to develop advanced RNA foundation models for precision oncology. The collaboration aims to improve the discovery and development of novel RNA-based therapeutics and biomarkers by generating higher-resolution transcriptomic insights. This marks another significant step in the convergence of AI and long-read sequencing for next-generation cancer therapies. (Link)
  9. Vital Signals raises over $15M led by XYZ Ventures to transform blood pressure management. San Francisco-based Vital Signals, founded by technology veteran Tom Moss, has raised more than $15 million in funding led by XYZ Ventures to advance its consumer blood pressure and long-term cardiovascular health platform. XYZ Ventures’ Ross Fubini described the company as having achieved a “technological breakthrough previously assumed to be impossible.” Proceeds will support product development and commercialization of its consumer-facing monitoring platform ahead of a planned Series A of $50–100 million. Moss previously held leadership roles at Google, Motorola, Razer, and Skydio. The funding addresses hypertension, which affects more than 100 million Americans and is often called the “silent killer.” (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 18th, 2026

LECO_Weekly-Healthcare-News_5-18-2026-1Download
  1. Boston Scientific Announces $1.5 billion Strategic Investment in MiRus LLC Boston Scientific Corporation (NYSE: BSX) announced a $1.5 billion strategic investment for an approximately 34% equity stake in MiRus LLC, a privately held company developing proprietary biomaterials, implants, and procedural solutions for cardiovascular and orthopedic diseases. Announced May 18, 2026, the agreement includes an exclusive option to acquire MiRus’ SIEGEL™ Balloon Expandable TAVR system, with potential additional payments of up to $3 billion upon clinical and regulatory milestones. The nickel-free, rhenium-alloy valve features a smaller delivery sheath, precise placement, and promising early clinical results in the ongoing STAR pivotal trial. The investment strengthens Boston Scientific’s interventional cardiology portfolio in the rapidly growing aortic stenosis market. (Link)
  2. J.P. Morgan, KKR, BofA Securities, and Barclays led the $478.7 million initial public offering of GMR Solutions (NYSE: GMRS) at a revised price of $15 per share GMR Solutions (NYSE: GMRS), the largest provider of emergency medical services in the U.S., priced its IPO at $15 per share, raising $478.7 million. The offering was led by a major syndicate including J.P. Morgan and KKR, with the latter also providing a $500 million concurrent private placement to bolster the company’s balance sheet. GMR Solutions plans to use the IPO proceeds primarily to pay down its existing debt. Despite the offering price being lowered from initial expectations, the IPO values the company at approximately $3.4 billion. The deal highlights significant institutional interest in the stabilization and growth potential of essential emergency and transport healthcare services. (Link)
  3. Prestige Consumer Healthcare (NYSE:PBH) Announces Acquisition of LaCorium Health Prestige Consumer Healthcare Inc. has entered into a definitive agreement to acquire LaCorium Health, a leading Australian platform in therapeutic skin care, lip, foot, and skin treatments. Announced May 13–14, 2026 alongside fiscal results, the approximately $150 million cash deal adds a high-growth, asset-light international OTC portfolio with strong market positions and expected double-digit revenue growth. The acquisition enhances Prestige’s dermatological offerings and geographic diversification. (Link)
  4. Lumexa Imaging (NASD: LMRI) executed its growth strategy by adding four new centers through joint ventures with University of Pittsburgh Medical Center (UPMC) and Advocate Health Lumexa Imaging the addition of four new locations in 2026, advancing its strategy to expand in high-growth markets via strategic partnerships. The expansion includes entry into the Pennsylvania market through a joint venture with the University of Pittsburgh Medical Center (UPMC) and further growth in the Southeast with Advocate Health. These additions, consisting of two acquisitions and two de novo centers, bring Lumexa’s total to over 190 outpatient imaging centers. The company leverages these joint ventures for capital efficiency and repeatability, focusing on the sustained shift toward outpatient, lower-cost sites of care driven by an aging population. (Link)
  5. Coastal Medical Transportation Systems Acquires Alert Ambulance to Expand New England Regional Care Network Coastal Medical Transportation Systems (CMTS), a leading privately owned medical transportation provider in New England, has completed the acquisition of Alert Ambulance Service. Announced May 18, 2026, the deal further strengthens CMTS’s position as one of the largest and most comprehensive ambulance and medical transportation providers in the region, following its prior integration of Fallon and Lifeline Ambulance Services. The acquisition expands geographic coverage across Massachusetts, New Hampshire, and Rhode Island, increases fleet size to over 325 vehicles, and grows the combined workforce to nearly 1,500 clinicians and support staff. (Link)
  6. Wellgistics Health (NASD: WGRX) Accelerates Digital Health Expansion with Planned Acquisition of WellCare Today Wellgistics Health, Inc. announced a non-binding letter of intent to acquire WellCare Today, a remote monitoring company specializing in RPM, RTM, and CCM programs powered by Samsung Galaxy Watch technology. Announced May 14, 2026, the proposed ~$15 million transaction (including $3 million cash and performance-based earnout in preferred stock) will integrate WellCare Today’s HealthAssist® platform with Wellgistics’ MSO pilot through Kare Clinicals and its network of over 6,500 independent pharmacies. The combination aims to enhance patient engagement, medication adherence, chronic care management, and reimbursement opportunities through wearable-enabled remote monitoring. (Link)
  7. Lorient Capital entered a strategic growth partnership with PeterMD to accelerate the national expansion of its proactive Medicine 3.0 healthcare platform Lorient Capital, a private equity firm exclusively focused on healthcare, has made a strategic investment in PeterMD to scale its personalized “Medicine 3.0” platform. PeterMD specializes in precision medicine, offering customized hormone health, longevity, and sexual wellness treatments through advanced diagnostics and proactive care. Lorient Capital is deploying capital from its $500 million Healthcare Fund III to fuel PeterMD’s national growth, aiming to transform the traditional reactive healthcare model. The partnership focuses on enhancing clinical outcomes and operational efficiency as PeterMD seeks to expand its footprint and bring precision-based integrated medicine to a broader national patient base. (Link)
  8. Blackstone and KKR & Co. Inc. reached a restructuring deal to take over the dental firm Affordable Care after slashing its total debt by 70% Direct lenders Blackstone and KKR are set to take control of Affordable Care, one of the largest U.S. dental services providers, following a major debt restructuring. The deal involves the lenders in a $1.4 billion private credit structure swapping their debt for equity, effectively slashing the dental firm’s debt load by approximately 70%. This restructuring provides Affordable Care with a significantly improved balance sheet to manage its extensive network of dental practices. The move underscores the increasing trend of major private credit lenders like Blackstone and KKR transitioning from creditors to equity owners to stabilize and preserve value in distressed healthcare portfolios. (Link)
  9. Quince Therapeutics (NASDAQ: QNCX)  Acquires Orphai Therapeutics and Raises up to $187 Million in Private Placement to Advance Pulmonary Pipeline Quince Therapeutics, Inc. announced the acquisition of Orphai Therapeutics, bringing in LAM-001, an inhaled formulation of rapamycin (sirolimus) for rare pulmonary diseases including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). Concurrently, Quince entered a private placement to raise up to $187 million ($115 million upfront + up to $72 million from warrants), led by Balyasny Asset Management with participation from a strong syndicate of healthcare investors. The combined proceeds are expected to fund operations through the end of 2028 and support multiple clinical milestones, including Phase 2 data readouts in 2027 and 2028.
  10. Orthopaedic Specialty Group and OrthoConnecticut Merge to Create Statewide Physician-Led Platform Powered by HOPCo Technology Partnership Orthopaedic Specialty Group (OSG) and OrthoConnecticut have officially merged, creating a dominant, physician-led musculoskeletal (MSK) care platform across Connecticut. The merger is bolstered by a strategic partnership with Healthcare Outcomes Performance Company (HOPCo), the global leader in MSK value-based care. While the organizations merge their clinical networks to improve patient access, HOPCo provides the digital infrastructure, including advanced analytics and care management tools, to optimize outcomes and reduce total care costs. This collaboration allows the unified practice to scale thoughtfully while preserving clinical autonomy and delivering high-quality orthopedic services closer to home for patients throughout the Connecticut. (Link)
  11. Sweetser merged with Common Ties Mental Health Services to create Maine’s largest provider of Certified Community Behavioral Health Clinic services Common Ties Mental Health Services, based in Lewiston, has officially merged with Sweetser to create a robust behavioral health network in Maine. This merger establishes Sweetser as the state’s largest provider of Certified Community Behavioral Health Clinic (CCBHC) services, integrating Common Ties’ regional expertise into Sweetser’s broad statewide platform. The investment focuses on streamlining mental health delivery, expanding free community training, and increasing access to specialized behavioral health services. By consolidating resources, the combined entity aims to build a more sustainable and accessible care model to address the rising mental health needs across Maine’s diverse and often underserved communities. (Link)
  12. Gryphon Investors-backed LEARN Behavioral acquired Little Leaves Behavioral Services from FullBloom, a portfolio company of American Securities LEARN Behavioral, a leading autism therapy provider backed by Gryphon Investors, has acquired Little Leaves Behavioral Services from FullBloom. FullBloom is a portfolio company of American Securities and sold the division to refocus on its core educational services. Little Leaves operates 18 early-intervention centers across Maryland, Virginia, and Florida, which will now join LEARN’s extensive national network. This acquisition allows LEARN Behavioral to expand its density in the Mid-Atlantic and establish a larger presence in the Florida market. The deal represents a significant consolidation within the ABA (Applied Behavior Analysis) sector, focusing on scaling early-intervention services for children with autism. (Link)
  13. Arcadea Group expanded its mission-critical software presence in Brazil through the acquisition of hemotherapy and hospital software provider Sofis Arcadea Group, a long-term investor in high-quality software firms, has acquired Sofis, a Rio de Janeiro-based provider of healthcare software. Sofis specializes in mission-critical solutions for blood bank management (hemotherapy) and hospital ERP systems, serving over 300 institutions across Brazil. This acquisition marks Arcadea’s fourth investment in the Brazilian healthcare technology market. Arcadea plans to leverage its permanent capital base to support Sofis’ long-term product development and international expansion. By transitioning from a founder-owned model to one backed by Arcadea’s global resources, Sofis aims to modernize its platform and deepen its penetration into the complex Latin American healthcare technology landscape. (Link)
  14. Iterative Health Acquires Cardiology Research Sites from NextStage Clinical Research Iterative Health, a healthcare technology and services company focused on accelerating clinical research, has acquired three cardiology research sites from NextStage Clinical Research in Texas (Beaumont, Port Arthur, and Waco). Announced on May 14, 2026, with Bourne Partners serving as financial advisor, the deal expands Iterative Health’s elite site network and strengthens its capabilities in cardiovascular research — a therapeutic area affecting nearly half of U.S. adults. The sites bring experienced teams, strong community provider connections, and an active trial portfolio, enhancing patient access to innovative therapies while providing sponsors with high-performing, real-world research centers. (Link)
  15. HealthScape Advisors Acquires PayerAlly to Strengthen Pharmacy Benefit Management Capabilities HealthScape Advisors, a leading payer advisory firm and a Chartis company, has acquired PayerAlly, an independent pharmacy consulting firm specializing in pharmacy benefit management (PBM) strategy, procurement, and optimization. Announced May 12, 2026 (with coverage extending through mid-May), the deal enhances HealthScape’s ability to help health plans and employers address rapidly rising prescription drug costs through integrated, clinically informed total cost-of-care solutions. PayerAlly’s expertise in PBM strategy complements HealthScape’s broader payer advisory platform, supporting more effective management of one of healthcare’s fastest-growing expense categories. (Link)
  16. NeuroVision Acquires Durin Life Sciences to Advance Neurodegenerative Diagnostics NeuroVision, a diagnostics company developing early detection tools for Alzheimer’s and other neurodegenerative diseases, has acquired Durin Life Sciences, a fellow diagnostics developer. Announced May 15, 2026, the deal adds Durin’s blood-based Duritect™ tests for early detection and monitoring of Alzheimer’s, Parkinson’s, and ALS. The combination accelerates NeuroVision’s platform for earlier, more accessible diagnosis and disease management, addressing critical gaps in neurodegenerative care. (Link)
  17. IKS Health Acquires ARAI Solutions to Accelerate Agentic AI Capabilities IKS Health, a global leader in care enablement and AI-driven clinical solutions, has acquired ARAI Solutions, a specialized AI management and technology company focused on biomedical knowledge graphs and clinical reasoning infrastructure. Announced May 13–14, 2026, the deal enhances IKS Health’s ability to build proprietary small language models and agentic AI systems for clinical, operational, and revenue cycle workflows. ARAI’s ontology layer and applied research expertise will improve the reliability, auditability, and efficiency of IKS’s AI platforms serving health systems nationwide. (Link)
  18. Signant Health Acquires Ametris to Create End-to-End eCOA and Digital Outcome Measures Platform Signant Health, a leading evidence generation company for clinical trials, has acquired Ametris (formerly ActiGraph), a global digital health solutions provider specializing in wearable-derived clinical outcome measures. The deal integrates Signant’s eCOA (electronic Clinical Outcome Assessment) solutions with Ametris’ validated sensor-based technologies for objective measurement of physical activity and function. The combined platform will deliver multimodal evidence—patient-reported outcomes alongside continuous real-world data—simplifying complex trials, accelerating insights, and strengthening regulatory submissions, particularly in CNS and other therapeutic areas. (Link)
  19. iSpecimen Inc. (NASD: ISPC) Secures $2.5 Million Private Placement to Support Operations Amid 89% Annual Stock Decline iSpecimen Inc. finalized a $2.5 million private placement on May 11, 2026, to bolster working capital. The biospecimen marketplace provider, currently valued at $3.39 million, has seen its share price plummet 89% over the past year to $4.57. This funding follows a $5.5 million raise in late 2025, aimed at mitigating rapid cash burn. iSpecimen, which connects medical researchers with specimen providers, will use the proceeds for general corporate purposes as it navigates significant financial challenges and seeks to stabilize its market position. (Link)
  20. Blue Sea Capital supported One Physics in its strategic acquisition and partnership with Petrone Associates to expand its Northeast clinical services footprint One Physics, the largest outsourced medical physics services company in North America, has announced its 22nd acquisition with the addition of New York-based Petrone Associates. This strategic move, backed by growth-oriented private equity firm Blue Sea Capital, significantly strengthens One Physics’ presence in the New York City metropolitan market and Northern New Jersey. The partnership leverages One Physics’ national scale and Petrone’s established clinical reputation to provide comprehensive diagnostic and therapy medical physics, radiation safety, and dosimetry services. Blue Sea Capital, managing over $1.5 billion in assets, remains committed to accelerating One Physics’ industry leadership through continued regional consolidation. (Link)

Venture Deals and Other

  1. Sound Ventures, Alumni Ventures, Link Ventures, Redesign Health, and RRE Ventures invested $17 million in Anomaly Insights to address healthcare payer-provider information asymmetry. Anomaly Insights, an AI-powered payer intelligence firm, secured $17 million in funding led by Sound Ventures to combat the informational gap between healthcare payers and providers. The investment includes participation from RRE Ventures and Redesign Health, focusing on Anomaly’s real-time AI platform that identifies and corrects billing errors and payment inaccuracies. The company aims to reduce the massive administrative waste in the U.S. healthcare system by providing transparency in the claims process. This new capital will be used to enhance Anomaly’s machine learning models and scale its solutions across larger health systems and insurance networks to streamline payment cycles. (Link)
  2. McKesson Ventures, FCA Venture Partners, Sanofi Ventures, and AIX Ventures led a $26 million Series A for Branchlab to scale its AI-driven biopharma commercialization platform Branchlab raised $26 million in a Series A round led by McKesson Ventures to accelerate the growth of its Pathwai™ platform. The round, which included corporate venture backing from Sanofi Ventures, brings Branchlab’s total funding to $35 million. The company uses privacy-first AI to optimize the patient journey and enhance pharmaceutical commercialization, reporting a 70% increase in patient activation efficiency. Branchlab intends to use the capital to expand its engineering and data science teams in New York and Colorado. By providing real-time insights to biopharma brands, Branchlab aims to make pharmaceutical marketing more effective and patient-centric through advanced data analytics. (Link)
  3. AIX Ventures led a $2 million pre-Seed funding round for Chromie Health to develop its autonomous AI-powered hospital workforce management platform Chromie Health, a New York-based startup, secured $2 million in pre-Seed funding led by AIX Ventures to tackle the hospital staffing crisis. The company develops autonomous AI agents that automate complex administrative tasks and workforce scheduling without requiring deep IT integration. Chromie Health’s platform is designed to alleviate the burnout of clinical staff by handling the logistics of hospital operations through intelligent automation. The investment will support the development of additional “digital agents” capable of reasoning through clinical context and staffing needs. This seed capital positions Chromie Health to pilot its solutions across more health systems seeking to modernize their operational efficiency. (Link)
  4. Blueprint Equity, Villain Capital, Z21 Ventures, and Bienville Capital led a $14 million growth funding round for pediatric-focused AI operating system Develo Develo, an AI-native operating system for pediatric practices, raised $14 million in a funding round led by Blueprint Equity. The platform integrates clinical workflows, billing, and parent engagement into a single AI-driven ecosystem, currently serving hundreds of providers across 25 states. The capital will be used to accelerate the development of specialized AI tools, including automated charge capture and AI-assisted scribing for pediatricians. Develo aims to reduce the administrative burden that leads to physician burnout while improving the financial performance of independent pediatric practices. The investment highlights a growing trend toward specialty-specific AI platforms that address unique clinical and operational workflows. (Link)
  5. Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC backed Forus with $160 million to build its AI-powered pharmaceutical delivery network Forus, formerly known as Tandem, raised $160 million in a major funding round backed by top-tier venture firms including Thrive Capital and General Catalyst. The company is building an AI-powered infrastructure that connects doctors, pharmacies, and biopharma companies to streamline the drug fulfillment process. Forus automates the “last-mile” clinical steps, such as insurance authorizations, to ensure patients receive treatments faster. With five of the top ten global biopharma companies already utilizing the network, Forus plans to use the investment to expand its nationwide reach and further integrate its AI layer into existing physician and pharmacy workflows to eliminate treatment delays. (Link)
  6. Uncork Capital, Frist Cressey Ventures, Moxxie Ventures, and Coalition Operators provided $11.6 million in Seed funding for the launch of Knit Health’s clinical behavior AI Knit Health, a spin-out from UC Berkeley, launched with $11.6 million in Seed funding co-led by Uncork Capital and Frist Cressey Ventures. The company is developing a Large Clinical Behavior Model (LCBM) trained on real-world clinician decisions across 30 U.S. health systems. Knit Health’s AI agents are designed to handle triage, patient flow, and care coordination by learning from collective clinical experience rather than just static text. The funding will be used to scale its foundational intelligence layer and deploy AI agents that assist in high-stakes hospital environments. This investment reflects a shift toward “Action AI” that can reason and perform complex tasks in clinical settings. (Link)
  7. Salesforce Ventures, Echo Health Ventures, Susa Ventures, Matrix Partners, and HC9 Ventures raised $17.5 million in Series A funding for Optura’s AI governance platform Optura, a Nashville-based healthcare AI governance platform, secured $17.5 million in Series A funding led by Salesforce Ventures. The investment, which brings Optura’s total funding to $25 million, will support the expansion of its “Return on AI Investment” (ROAI) platform. Optura helps enterprise healthcare organizations, such as Independence Blue Cross, map fragmented data and measure the efficacy of their AI agents. The capital will be used to scale partnerships with LLM providers and grow its engineering teams. By providing a unified knowledge layer, Optura enables healthcare leaders to prioritize AI use cases based on actual operational readiness and projected business value. (Link)
  8. Norwest, Primary, Next Ventures, Constellation, and Scrub Capital led a $25 million financing round for Tokaido Health to launch its AI medication steerage platform. Tokaido Health emerged from stealth with $25 million in funding led by Norwest and Primary to address skyrocketing pharmacy costs for employers. The platform utilizes AI and behavioral economics to identify same-or-better medications that cost less, steering members toward high-value options like biosimilars. Tokaido layers on top of existing PBM stacks, allowing for a seamless integration without plan redesigns. The investment will be used to scale its concierge-style member outreach and expand its clinical reasoning engine. By focusing on site-of-care steerage and polypharmacy reconciliation, Tokaido aims to eliminate billions in wasted drug spending while improving the patient experience. (Link)
  9. Andera Partners, American Century Investments, Clarevia Ventures, Time BioVentures, View Ventures, Cadence Healthcare Ventures, and Anduril Investors led a $20 million Series D for Rivermark Medical Rivermark Medical, a urology-focused medical device company, raised $20 million in Series D funding led by Andera Partners. The financing will support the ongoing RAPID III pivotal clinical trial for the FloStent™ System, a non-surgical treatment for men with benign prostatic hyperplasia (BPH). The investment syndicate includes American Century Investments and Time BioVentures, focusing on bringing this reversible, office-based therapy to market. The FloStent is designed to be easily adjustable and tissue-preserving, offering a first-line alternative to more invasive surgical procedures. The capital will also be used to prepare for a U.S. commercial launch following expected regulatory approval. (Link)
  10. Aulis Capital led a $13.4 million Seed funding round for Shyld AI to accelerate the deployment of its autonomous AI-driven infection control solutions Shyld AI, a healthcare technology company, secured $13.4 million in Seed funding led by Aulis Capital to expand its active intelligence solutions for hospital facilities. Shyld AI develops autonomous physical agents that use AI and UV disinfection to reduce environmental contamination in high-risk areas like operating rooms. The funding will accelerate deployments across U.S. health systems and support the company’s expansion into regulated pharmaceutical manufacturing environments. By streamlining infection control and compliance without adding to the workload of hospital staff, Shyld AI aims to improve patient safety and operational efficiency. The investment marks a significant milestone in the adoption of autonomous hygiene agents in healthcare. (Link)

Sign up for all the Lawrence, Evans & Co., LLC news and activities
CLICK HERE